Flush with cash from its coronavirus success, Pfizer went on a buying spree, shelling out more than $US60 billion to expand into therapies for immune diseases, migraines, sickle cell disease and respiratory syncytial virus. The centrepiece purchase was the $US43 billion acquisition of Seagen, a cancer company with a precision-missile-like approach to targeting tumours.
But then the world moved on from coronavirus faster than Pfizer had anticipated, company executives have said, with fewer people opting to get its vaccine.
The company’s revenue went into free fall, sinking to $US58.5 billion in 2023, and its share price followed suit. Bourla didn’t receive a cash bonus that year, and his compensation, valued at $US21.6 million, was a 35 per cent pay cut from the previous year.
Bourla acknowledged in a May interview with The Washington Post that “we missed big-time our internal projections” for coronavirus.
Meanwhile, Wall Street has a new fixation: diabetes and weight-loss drugs pioneered by Eli Lilly and Novo Nordisk. Pfizer has yet to distinguish itself in the increasingly competitive race for weight-loss primacy, and is continuing to work on a weight-loss pill.
Bourla said in the May interview that the company “will be a significant player in obesity going forward.” Still, he said in the interview he believes that the market for cancer drugs is far bigger and will be one of Pfizer’s main engines of growth.
Bourla has often invoked his life story in articulating his vision and drive. He grew up part of Greece’s Jewish minority, “so that taught me how to be able to fight, for nothing is given,” he said at a 2022 Goldman Sachs conference, according to a transcript compiled by S&P Global Market Intelligence. Trained as a veterinarian, Bourla spent much of his career at Pfizer’s animal health division, where he learned “how to act without the resources” of the larger company.
Loading
As Bourla has navigated through leaner times, he has taken a knife to the company’s operations. Pfizer announced a plan last October to cut $US3.5 billion in costs. Then in May, it unveiled an effort to save another $US1.5 billion by the end of 2027. The frugal measures have yet to win over Wall Street, and its share price is roughly unchanged so far this year.
There have been some setbacks. In September, Pfizer said it was voluntarily withdrawing Oxbryta, a treatment for sickle cell disease approved in 2019 by the Food and Drug Administration that it acquired in its $US5.4 billion purchase of Global Blood Therapeutics, citing patient deaths.
“It’s hard to find a headline that’s truly jarring” in the world of pharmaceuticals, wrote Jefferies analyst Akash Tewari, but withdrawing Oxbryta and discontinuing active trials of the drug “fits the bill.”
Loading
Starboard hasn’t publicly disclosed what changes it is seeking but said it plans to present its views to Bourla and the board on Wednesday.
Starboard on Thursday alleged that Pfizer or its representatives tried to intimidate two former executives who had reportedly offered to help Starboard’s efforts, saying they were threatened with litigation and having their pay clawed back unless they publicly supported Bourla.
The allegations came a day after the two men – former CEO Ian Read and former finance chief Frank D’Amelio – said in a statement released by an investment firm that they “decided not to be involved” in Starboard’s efforts and are “fully supportive” of Bourla, his executive team and Pfizer’s board.
Starboard asked Pfizer’s board to probe the matter, calling it “highly inappropriate, flagrantly unethical, and a significant breach of fiduciary obligations.”
The Washington Post
The Business Briefing newsletter delivers major stories, exclusive coverage and expert opinion. Sign up to get it every weekday morning.
